Clinical Trials
The Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute of the Lurie Cancer Center is committed to providing the most advanced treatments available for patients with brain and spine tumors, and to developing clinical research that will lead to tomorrow’s care.
For best results, use specific search terms (e.g., "glioblastoma" instead of "brain tumor") below. We do our best to keep these listings up-to-date, but we may sometimes have trials available that are not yet listed. To inquire about other clinical trials or to learn more about the clinical trials listed here, please contact cancertrials@northwestern.edu or call 312-695-1102. You can also view a list of open Lurie Cancer Center clinical trials for all types of cancer.
Phase 1/2 trial of blood-brain barrier opening with the SonoCloud-9 implantable ultrasound device and treatment with albumin-bound paclitaxel in patients with recurrent glioblastomaEligible patients will undergo craniotomy for tumor resection. During the tumor resection and when possible, an initial low dose of albumin-bound paclitaxel will be given following sonication. In select patients, the sonication procedure may occur immediately after the test dose of chemotherapy is administered. The sonication device will be implanted at the end of the procedure. In phase 1, about two weeks after surgery, patients will undergo sonication and albumin-bound paclitaxel administration with MRI to quantify extent of blood brain barrier opening. Sonication and administration of albumin-bound paclitaxel will continue every 3 weeks until disease progression. The planned albumin-bound paclitaxel starting dose is 40 mg/m2, to be escalated in the absence of significant toxicity up to 260 mg/m2. Blood samples for circulating tumor DNA will also be collected before and after each sonication. In phase 2, pre-sonication carboplatin at AUC 5 will be added to the regimen, with a safety run-in for the first 6 patients. Inclusion Criteria: Measurable or evaluable disease For patients with a childbearing potential Exclusion Criteria: Have multifocal disease that cannot be encompassed in the ultrasound fields:
NCT04528680 STU00212298 |